Advertisement

Picture Bionordic Nordic Life Science Days 2018 Stockholm 600x60px
Document › Details

Arsanis, Inc.. (3/5/18). "Press Release: Arsanis to Present at the 38th Annual Cowen and Company Health Care Conference". Waltham, MA & Vienna.

Organisations Organisation Arsanis Inc. (Nasdaq: ASNS)
  Group Arsanis (Group)
  Organisation 2 Cowen & Company LLC
  Group Cowen (Group)
Products Product Cowen & Co. Annual Health Care Conference 2018 Boston
  Product 2 ASN100 (Arsanis)
Index term Index term Arsanis–Cowen: investor conference, 201803 supply service Arsanis presents at Cowen & Co Annual Health Care Conference 2018
Persons Person Russo, René (Arsanis 201702 CEO)
  Person 2 Gibbs, Krystle (Ten Bridge Communications 201703)
     


Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, announced today that CEO René Russo, PharmD, BCPS, will present a company overview at the 38th Annual Cowen and Company Health Care Conference on March 12, 2018, at 12:00 p.m. ET.

A webcast of the presentation will be available on the Arsanis website under “Events and Presentations” or can be accessed at http://wsw.com/webcast/cowen46/asns/. The webcast will be archived for 30 days following the live presentation.


About Arsanis

Arsanis, Inc. is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build and advance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets. The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in a Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.

Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).


For more information, please visit the Arsanis website at www.arsanis.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180305005420/en/

Source: Arsanis, Inc.


Media:
Ten Bridge Communications
Krystle Gibbs, 508-479-6358
krystle@tenbridgecommunications.com

or

Investor:
Michael Gray, 781-819-5201
Chief Operating and Chief Financial Officer
mike.gray@arsanis.com

   
Record changed: 2018-03-22

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 600x80px

More documents for Arsanis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2018 Boston September 600x60px




» top